Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis

Parkinsonism and Related Disorders

Volumn 21, Issue 8, 2015, Pages 833-842

  Bomasang Layno, Emily ^a   Fadlon, Iris ^a   Murray, Andrea N ^a   Himelhoch, Seth ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Depression; Meta analysis; Parkinson's disease; Systematic review; Treatment

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CITALOPRAM; DESIPRAMINE; DOXEPIN; FLUOXETINE; MEMANTINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; SERTRALINE; TRAZODONE; VENLAFAXINE; SEROTONIN UPTAKE INHIBITOR;

ABSENCE OF SIDE EFFECTS; AGE DISTRIBUTION; BEHAVIOR THERAPY; BRADYKINESIA; CLINICAL EFFECTIVENESS; DEPRESSION; EVIDENCE BASED MEDICINE; HEART DISEASE; HUMAN; HYPERTENSION; META ANALYSIS; PARKINSON DISEASE; PHOTOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SEX DIFFERENCE; SYSTEMATIC REVIEW; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; COGNITIVE THERAPY; COMPLICATION; PROCEDURES;

COGNITIVE THERAPY; DEPRESSION; HUMANS; PARKINSON DISEASE; SEROTONIN UPTAKE INHIBITORS;

EID: 84937520043     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.04.018     Document Type: Review

References (74)

1. Beitz J.M. Parkinson's disease: a review. Front. Biosci. (Schol. Ed.) 2014, 6:65-74. doi: S415 [pii].
2. Veazey C., Aki S.O., Cook K.F., Lai E.C., Kunik M.E. Prevalence and treatment of depression in Parkinson's disease. J.Neuropsychiatry Clin. Neurosci. 2005, 17(3):310-323. 10.1176/appi.neuropsych.17.3.310.
3. Aarsland D., Marsh L., Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov. Disord. 2009, 24(15):2175-2186. 10.1002/mds.22589.
4. Adler C.H. Nonmotor complications in Parkinson's disease. Mov. Disord. 2005, 20(Suppl.11):S23-S29. 10.1002/mds.20460.
5. Reijnders J.S., Ehrt U., Weber W.E., Aarsland D., Leentjens A.F. Asystematic review of prevalence studies of depression in Parkinson's disease. Mov. Disord. 2008, 23(2):183-189. quiz 313. 10.1002/mds.21803.
6. Richard I.H., Frank S., McDermott M.P., et al. The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations. Cogn. Behav. Neurol. 2004, 17(4):201-207. doi: 00146965-200412000-00004 [pii].
7. Vajda F.J., Solinas C. Current approaches to management of depression in Parkinson's disease. J.Clin. Neurosci. 2005, 12(7):739-743. 10.1016/j.jocn.2005.03.008.
8. Soh S.E., Morris M.E., McGinley J.L. Determinants of health-related quality of life in Parkinson's disease: a systematic review. Park. Relat. Disord. 2011, 17(1):1-9. 10.1016/j.parkreldis.2010.08.012.
9. Aarsland D., Larsen J.P., Karlsen K., Lim N.G., Tandberg E. Mental symptoms in Parkinson's disease are important contributors to caregiver distress. Int. J. Geriatr. Psychiatry 1999, 14(10):866-874. 10.1002/(SICI)1099-1166(199910)14:10<866::AID-GPS38>3.0.CO;2-Z.
10. Leiknes I., Tysnes O.B., Aarsland D., Larsen J.P. Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: The norwegian ParkWest study. Acta Neurol. Scand. 2010, 122(6):418-424. 10.1111/j.1600-0404.2010.01332.x.
11. Schrag A., Hovris A., Morley D., Quinn N., Jahanshahi M. Caregiver-burden in Parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Park. Relat. Disord. 2006, 12(1):35-41. doi: S1353-8020(05)00143-4 [pii].
12. Menza M., Dobkin R.D., Marin H., et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Mov. Disord. 2009, 24(9):1325-1332. 10.1002/mds.22586.
13. Dobkin R.D., Troster A.I., Rubino J.T., et al. Neuropsychological outcomes after psychosocial intervention for depression in Parkinson's disease. J.Neuropsychiatry Clin. Neurosci. 2014, 26(1):57-63. 10.1176/appi.neuropsych.12120381.
14. Chung T.H., Deane K.H., Ghazi-Noori S., Rickards H., Clarke C.E. Systematic review of antidepressant therapies in Parkinson's disease. Park. Relat. Disord. 2003, 10(2):59-65.
15. Skapinakis P., Bakola E., Salanti G., Lewis G., Kyritsis A.P., Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 2010, 10. 49-2377-10-49. 10.1186/1471-2377-10-49.
16. Price A., Rayner L., Okon-Rocha E., et al. Antidepressants for the treatment of depression in neurological disorders: A systematic review and meta-analysis of randomised controlled trials. J.Neurol. Neurosurg. Psychiatry 2011, 82(8):914-923. 10.1136/jnnp.2010.230862.
17. Miyasaki J.M., Shannon K., Voon V., et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the quality standards subcommittee of the american academy of neurology. Neurology 2006, 66(7):996-1002. 10.1212/01.wnl.0000215428.46057.3d.
18. Weintraub D., Morales K.H., Moberg P.J., et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov. Disord. 2005, 20(9):1161-1169. 10.1002/mds.20555.
19. Seppi K., Weintraub D., Coelho M., et al. The movement disorder society evidence-based medicine review update: Treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 2011, 26(Suppl.3):S42-S80. 10.1002/mds.23884.
20. Shabnam G.N., Th C., Kho D., H R, Ce C. Therapies for depression in Parkinson's disease. Cochrane Database Syst. Rev. 2003, (3). CD003465. 10.1002/14651858.CD003465.
21. Rocha F.L., Murad M.G., Stumpf B.P., Hara C., Fuzikawa C. Antidepressants for depression in Parkinson's disease: systematic review and meta-analysis. J.Psychopharmacol. 2013, 27(5):417-423. 10.1177/0269881113478282.
22. Troeung L., Egan S.J., Gasson N. Ameta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease. PLoS One 2013, 8(11):e79510. 10.1371/journal.pone.0079510.
23. Yang S., Sajatovic M., Walter B.L. Psychosocial interventions for depression and anxiety in Parkinson's disease. J.Geriatr. Psychiatry Neurol. 2012, 25(2):113-121. 10.1177/0891988712445096.
24. Liu J., Dong J., Wang L., Su Y., Yan P., Sun S. Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. PLoS One 2013, 8(10):e76651. 10.1371/journal.pone.0076651.
25. Navan P., Findley L.J., Jeffs J.A., Pearce R.K., Bain P.G. Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on parkinsonian tremor. Mov. Disord. 2003, 18(11):1324-1331. 10.1002/mds.10538.
26. Rios Romenets S., Creti L., Fichten C., et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease - a randomized study. Park. Relat. Disord. 2013, 19(7):670-675. 10.1016/j.parkreldis.2013.03.003.
27. Okai D., Askey-Jones S., Samuel M., et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology 2013, 80(9):792-799. 10.1212/WNL.0b013e3182840678.
28. Stallibrass C., Sissons P., Chalmers C. Randomized controlled trial of the alexander technique for idiopathic Parkinson's disease. Clin. Rehabil. 2002, 16(7):695-708.
29. Leentjens A.F., Vreeling F.W., Luijckx G.J., Verhey F.R. SSRIs in the treatment of depression in Parkinson's disease. Int. J. Geriatr. Psychiatry 2003, 18(6):552-554. 10.1002/gps.865.
30. Devos D., Dujardin K., Poirot I., et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov. Disord. 2008, 23(6):850-857. 10.1002/mds.21966.
31. Menza M., Dobkin R.D., Marin H., et al. Acontrolled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009, 72(10):886-892. 10.1212/01.wnl.0000336340.89821.b3.
32. Ondo W.G., Shinawi L., Davidson A., Lai D. Memantine for non-motor features of Parkinson's disease: a double-blind placebo controlled exploratory pilot trial. Park. Relat. Disord. 2011, 17(3):156-159. 10.1016/j.parkreldis.2010.12.003.
33. Richard I.H., McDermott M.P., Kurlan R., et al. Arandomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012, 78(16):1229-1236. 10.1212/WNL.0b013e3182516244.
34. Rios Romenets S., Creti L., Fichten C., Bailes S., Libman E., Pelletier A., Postuma R.B. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease - a randomized study. Park. Relat. Disord. 2013, 19:670-675.
35. Weintraub D., Mavandadi S., Mamikonyan E., et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010, 75(5):448-455. 10.1212/WNL.0b013e3181ebdd79.
36. Wermuth L., Sorensen P.S., Timm S., et al. Depression in idiopathic Parkinson's disease treated with citalopram. A placebo-controlled trial. Nord. J. Psychiatry 1998, 52(2):163-169.
37. Werneck A.L., Rosso A.L., Vincent M.B. The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease. Arq. Neuropsiquiatr. 2009, 67(2B):407-412.
38. Antonini A., Tesei S., Zecchinelli A., et al. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: Effect on quality of life. Mov. Disord. 2006, 21(8):1119-1122. 10.1002/mds.20895.
39. Avila A., Cardona X., Martin-Baranera M., Maho P., Sastre F., Bello J. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J.Clin. Psychopharmacol. 2003, 23(5):509-513. 10.1097/01.jcp.0000088908.24613.db.
40. Rektorova I., Rektor I., Bares M., et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur. J. Neurol. 2003, 10(4):399-406.
41. Sproesser E., Viana M.A., Quagliato E.M., de Souza E.A. The effect of psychotherapy in patients with PD: A controlled study. Park. Relat. Disord. 2010, 16(4):298-300. 10.1016/j.parkreldis.2009.08.008.
42. Veazey C., Cook K.F., Stanley M., Lai E.C., Kunik M.E. Telephone-administered cognitive behavioral therapy: a case study of anxiety and depression in Parkinson's disease. J.Clin. Psychol. Med. Settings 2009, 16(3):243-253. 10.1007/s10880-009-9167-6.
43. Dobkin R.D., Menza M., Allen L.A., et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Am. J. Psychiatry 2011, 168(10):1066-1074. 10.1176/appi.ajp.2011.10111669.
44. Fregni F., Santos C.M., Myczkowski M.L., et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J.Neurol. Neurosurg. Psychiatry 2004, 75(8):1171-1174. 10.1136/jnnp.2003.027060.
45. Pal E., Nagy F., Aschermann Z., Balazs E., Kovacs N. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson's disease: a randomized, double-blind, placebo-controlled study. Mov. Disord. 2010, 25(14):2311-2317. 10.1002/mds.23270.
46. Fregni F., Ono C.R., Santos C.M., et al. Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD. Neurology 2006, 66(11):1629-1637. 10.1212/01.wnl.0000218194.12054.60.
47. Skapinakis P., Bakola E., Salanti G., Lewis G., Kyritsis A.P., Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 2010, 10. 49-2377-10-49. 10.1186/1471-2377-10-49.
48. Shabnam G.N., Th C., Kho D., H R, Ce C. Therapies for depression in Parkinson's disease. Cochrane Database Syst. Rev. 2003, 3. CD003465. 10.1002/14651858.CD003465.
49. Rios Romenets S., Creti L., Fichten C., et al. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease - a randomized study. Park. Relat. Disord. 2013, 19(7):670-675. 10.1016/j.parkreldis.2013.03.003.
50. Werneck A.L., Rosso A.L., Vincent M.B. The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease. Arq. Neuropsiquiatr. 2009, 67(2B):407-412.
51. Lidstone S.C., Schulzer M., Dinelle K., et al. Effects of expectation on placebo-induced dopamine release in Parkinson disease. Arch. Gen. Psychiatry 2010, 67(8):857-865. 10.1001/archgenpsychiatry.2010.88.
52. de la Fuente-Fernandez R., Schulzer M., Stoessl A.J. Placebo mechanisms and reward circuitry: clues from Parkinson's disease. Biol. Psychiatry 2004, 56(2):67-71. 10.1016/j.biopsych.2003.11.019.
53. de la Fuente-Fernandez R. The placebo-reward hypothesis: dopamine and the placebo effect. Park. Relat. Disord. 2009, 15(Suppl.3):S72-S74. 10.1016/S1353-8020(09)70785-0.
54. Schrag A., Jahanshahi M., Quinn N.P. What contributes to depression in Parkinson's disease?. Psychol. Med. 2001, 31(1):65-73.
55. Remy P., Doder M., Lees A., Turjanski N., Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128(Pt 6):1314-1322. 10.1093/brain/awh445.
56. Okun M.S., Fernandez H.H. Will tricyclic antidepressants make a comeback for depressed Parkinson disease patients?. Neurology 2009, 72(10):868-869. http://search.ebscohost.com/login.aspx?direct=true%26db=psyh%26AN=2009-03542-001%26site=ehost-live, 10.1212/01.wnl.0000338145.24512.02.
57. Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. J.Neurol. Neurosurg. Psychiatry 2005, 76(Suppl 1):i48-i52. 10.1136/jnnp.2004.060426.
58. Gallagher D.A., Schrag A. Psychosis, apathy, depression and anxiety in Parkinson's disease. Neurobiol. Dis. 2012, 46(3):581-589. 10.1016/j.nbd.2011.12.041.
59. Dell'Agnello G., Ceravolo R., Nuti A., et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin. Neuropharmacol. 2001, 24(4):221-227.
60. van de Vijver D.A., Roos R.A., Jansen P.A., Porsius A.J., de Boer A. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br. J. Clin. Pharmacol. 2002, 54(2):168-170.
61. Linazasoro G. Worsening of Parkinson's disease by citalopram. Park. Relat. Disord. 2000, 6(2):111-113.
62. Rampello L., Chiechio S., Raffaele R., Vecchio I., Nicoletti F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin. Neuropharmacol. 2002, 25(1):21-24.
63. Leentjens A.F., Koester J., Fruh B., Shephard D.T., Barone P., Houben J.J. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin. Ther. 2009, 31(1):89-98. 10.1016/j.clinthera.2009.01.012.
64. Barone P., Poewe W., Albrecht S., et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010, 9(6):573-580. 10.1016/S1474-4422(10)70106-X.
65. Leentjens A.F. The role of dopamine agonists in the treatment of depression in patients with Parkinson's disease: a systematic review. Drugs 2011, 71(3):273-286. 10.2165/11585380-000000000-00000.
66. Carpenter L.L., Milosavljevic N., Schecter J.M., Tyrka A.R., Price L.H. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J.Clin. Psychiatry 2005, 66(10):1234-1238.
67. Schrag A., Barone P., Brown R.G., et al. Depression rating scales in Parkinson's disease: Critique and recommendations. Mov. Disord. 2007, 22(8):1077-1092. 10.1002/mds.21333.
68. Farabaugh A., Locascio J.J., Yap L., et al. Cognitive-behavioral therapy for patients with Parkinson's disease and comorbid major depressive disorder. Psychosomatics 2010, 51(2):124-129. 10.1176/appi.psy.51.2.124.
69. Dobkin R.D., Allen L.A., Menza M. Cognitive-behavioral therapy for depression in Parkinson's disease: a pilot study. Mov. Disord. 2007, 22(7):946-952. 10.1002/mds.21455.
70. Voon V., Sohr M., Lang A.E., et al. Impulse control disorders in Parkinson disease: a multicenter case-control study. Ann. Neurol. 2011, 69(6):986-996. 10.1002/ana.22356.
71. Voon V., Dalley J.W. Parkinson disease: impulsive choice-Parkinson disease and dopaminergic therapy. Nat. Rev. Neurol. 2011, 7(10):541-542. 10.1038/nrneurol.2011.139.
72. Okai D., Samuel M., Askey-Jones S., David A.S., Brown R.G. Impulse control disorders and dopamine dysregulation in Parkinson's disease: a broader conceptual framework. Eur. J. Neurol. 2011, 18(12):1379-1383. 10.1111/j.1468-1331.2011.03432.x.
73. Dobkin R.D., Menza M., Allen L.A., et al. Telephone-based cognitive-behavioral therapy for depression in Parkinson disease. J.Geriatr. Psychiatry Neurol. 2011, 24(4):206-214. 10.1177/0891988711422529.
74. Yang S., Sajatovic M., Walter B.L. Psychosocial interventions for depression and anxiety in Parkinson's disease. J.Geriatr. Psychiatry Neurol. 2012, 25(2):113-121. 10.1177/0891988712445096.